Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 17Terminated 2No longer available 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Hodgkin Disease 8Lymphoma, Large-Cell, Anaplastic 6Lymphoma 5Lymphoma, T-Cell, Peripheral 4Lymphoma, Large B-Cell, Diffuse 4Lymphoma, Non-Hodgkin 3Recurrence 2Neoplasms, Germ Cell and Embryonal 2Lymphoma, B-Cell 2Lymphatic Diseases 2Hematologic Diseases 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Nonseminomatous germ cell tumor 1Neoplasms by Histologic Type 1Neoplasms 1Mycosis Fungoides 1Melanoma 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1

Interventions

Rituximab 4Cyclophosphamide 4Etoposide 3Dexamethasone 3ponatinib 2pomalidomide 2fludarabine 2Whole-Body Irradiation 2Vincristine 2Sirolimus 2Prednisone 2Platelet Transfusion 2Mycophenolic Acid 2Lenalidomide 2Ifosfamide 2Doxorubicin 2Carboplatin 2Busulfan 2Brentuximab Vedotin 2Alemtuzumab 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2ricolinostat 1pembrolizumab 1nilotinib 1ibrutinib 1fludarabine phosphate 1epratuzumab 1daratumumab 1dacetuzumab 1Tacrolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Hematologic Diseases × Brentuximab Vedotin × Clear all
NCT01925612 2018-06-21

Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)

Seagen Inc.

Phase 2 Terminated
87 enrolled 18 charts
Lymphoid

Hematologic Diseases, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00649584 2014-12-18

A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies

Seagen Inc.

Phase 1 Terminated
44 enrolled
Lymphoid

Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡